{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:08:07Z","timestamp":1772492887103,"version":"3.50.1"},"reference-count":52,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novo Nordisk Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>GH treatment in children with idiopathic short stature (ISS) can be controversial, and analyses comparing responses to children with GH deficiency (GHD) are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To compare the effectiveness and safety of GH treatment in children with ISS and GHD, including those reaching near adult height (NAH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This post hoc analysis of the NordiNet International Outcome Study (2006-2016) and the American Norditropin Studies: Web-Enabled Research Program (2002-2016) included children with ISS or GHD who initiated treatment aged &amp;lt;18 years. The safety analysis set had birthdate and GH exposure information. The effectiveness analysis set was GH-na\u00efve with valid baseline information. GH exposure, effectiveness, and safety outcomes were analyzed annually for \u226410 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The safety analysis set included 3816 children with ISS and 22 858 with GHD. The effectiveness analysis set comprised 18 405 children (ISS: 2684; GHD: 15 721), 1856 of whom reached NAH (ISS: 230; GHD: 1626). Average dose of GH was higher for children with ISS vs children with GHD but mean duration of treatment was shorter. At NAH, height SD score (mean [SD]) was \u22121.21 (1.09) and \u22120.90 (1.20) for children with ISS and GHD, respectively, whereas change in height SD score (mean [SD]) from baseline to 10 years was 1.21 (0.86) and 1.45 (1.09). Incidence of adverse reactions was similar across indications, with no new safety signals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>GH treatment over 5 to 10 years effectively increased height in children with ISS and children with GHD, including those who reached NAH, with a favorable benefit-risk profile.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvaf133","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T11:59:21Z","timestamp":1755172761000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparative Outcomes of GH Treatment in Pediatric Idiopathic Short Stature and GH Deficiency"],"prefix":"10.1210","volume":"9","author":[{"given":"Moshe","family":"Phillip","sequence":"first","affiliation":[{"name":"Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel , Petah Tikva 4920235 ,","place":["Israel"]},{"name":"Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv 6997801 ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Jennifer","family":"Abuzzahab","sequence":"additional","affiliation":[{"name":"Diabetes and Endocrine Center, Children's Minnesota , Saint Paul, MN 55102 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Pietropoli","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Novo Nordisk Health Care AG \u00a0 Zurich 8058 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Ferran","sequence":"additional","affiliation":[{"name":"Data Science, Qualiance ApS , Copenhagen 1663 ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"H\u00f8jby","sequence":"additional","affiliation":[{"name":"Clinical Drug Development, Novo Nordisk A\/S , S\u00f8borg 2860 ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2445-2338","authenticated-orcid":false,"given":"Nicky","family":"Kelepouris","sequence":"additional","affiliation":[{"name":"US Medical Affairs, Rare Endocrine Disorders, Novo Nordisk Inc , Plainsboro, NJ 08536 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Primo\u017e","family":"Kotnik","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical Faculty, University of Ljubljana , Ljubljana 1000 ,","place":["Slovenia"]},{"name":"Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children's Hospital Ljubljana, University Medical Center , Ljubljana 1000 ,","place":["Slovenia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Polak","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology, Gynecology and Diabetology, H\u00f4pital Universitaire Necker Enfants Malades, Assistance Publique-H\u00f4pitaux de Paris Universit\u00e9 Paris Cit\u00e9, INSERM U1016, Institut IMAGINE, Centre de R\u00e9f\u00e9rence des Maladies Endocriniennes Rares de la Croissance et du D\u00e9veloppement , Paris 75015 ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1067-4976","authenticated-orcid":false,"given":"Lars","family":"S\u00e4vendahl","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet \u00a0 Solna 171 77 ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"issue":"2","key":"2025092606220913600_bvaf133-B1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ghir.2007.11.004","article-title":"Idiopathic short stature: definition, epidemiology, and diagnostic evaluation","volume":"18","author":"Wit","year":"2008","journal-title":"Growth Horm IGF Res"},{"key":"2025092606220913600_bvaf133-B2","volume-title":"Endotext","author":"Yau","year":"2000"},{"issue":"7","key":"2025092606220913600_bvaf133-B3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.eprac.2024.04.009","article-title":"Children with idiopathic short stature: an expanding role for genetic investigation in their medical evaluation","volume":"30","author":"Cohen","year":"2024","journal-title":"Endocr Pract"},{"issue":"1","key":"2025092606220913600_bvaf133-B4","doi-asserted-by":"crossref","first-page":"lvac005","DOI":"10.1093\/ejendo\/lvac005","article-title":"Long-acting PEGylated growth hormone in children with idiopathic short stature: time to reconsider our diagnostic and treatment policy?","volume":"188","author":"Wit","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2025092606220913600_bvaf133-B5","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1210\/jc.2008-0509","article-title":"Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop","volume":"93","author":"Cohen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2025092606220913600_bvaf133-B6","first-page":"Cd004440","article-title":"Recombinant growth hormone for idiopathic short stature in children and adolescents","volume":"3","author":"Bryant","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2025092606220913600_bvaf133-B7","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1515\/jpem-2020-0287","article-title":"The effect of treatment with recombinant human growth hormone (rhGH) on linear growth and adult height in children with idiopathic short stature (ISS): a systematic review and meta-analysis","volume":"33","author":"Paltoglou","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"01","key":"2025092606220913600_bvaf133-B8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-0043-1778678","article-title":"A systematic review of the impact of growth hormone therapy on final adult height of children with idiopathic short stature","volume":"07","author":"Muammar","year":"2024","journal-title":"J Diabetes Endocrine Practice"},{"issue":"6","key":"2025092606220913600_bvaf133-B9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000452150","article-title":"Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency","volume":"86","author":"Grimberg","year":"2016","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"2025092606220913600_bvaf133-B10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000496353","article-title":"Quality of life in adolescent boys with idiopathic short stature: positive impact of growth hormone and aromatase inhibitors","volume":"90","author":"Bullinger","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2025092606220913600_bvaf133-B11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1590\/0004-2730000002793","article-title":"Comparison between the growth response to growth hormone (GH) therapy in children with partial GH insensitivity or mild GH deficiency","volume":"58","author":"Cardoso","year":"2014","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"4","key":"2025092606220913600_bvaf133-B12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000322937","article-title":"Improvements in behaviour and self-esteem following growth hormone treatment in short prepubertal children","volume":"75","author":"Chaplin","year":"2011","journal-title":"Horm Res Paediatr"},{"issue":"10","key":"2025092606220913600_bvaf133-B13","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1210\/jc.2004-0791","article-title":"Psychological adaptation in children with idiopathic short stature treated with growth hormone or placebo","volume":"89","author":"Ross","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025092606220913600_bvaf133-B14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1067\/S0022-3476(03)00395-0","article-title":"Quality of life and self-esteem in children treated for idiopathic short stature","volume":"143","author":"Sandberg","year":"2003","journal-title":"J Pediatr"},{"issue":"3","key":"2025092606220913600_bvaf133-B15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4008\/jcrpe.v1i3.53","article-title":"Controversies in the definition and treatment of idiopathic short stature (ISS)","volume":"1","author":"Pedicelli","year":"2009","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"4-5","key":"2025092606220913600_bvaf133-B16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000185025","article-title":"Growth hormone treatment of idiopathic short stature","volume":"46","author":"Hintz","year":"1996","journal-title":"Horm Res"},{"issue":"2","key":"2025092606220913600_bvaf133-B17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000347121","article-title":"Towards optimal treatment with growth hormone in short children and adolescents: evidence and theses","volume":"79","author":"Ranke","year":"2013","journal-title":"Horm Res Paediatr"},{"issue":"Suppl 2","key":"2025092606220913600_bvaf133-B18","first-page":"41","article-title":"The growth hormone cascade: progress and long-term results of growth hormone treatment in growth hormone deficiency","volume":"49","author":"Grumbach","year":"1998","journal-title":"Horm Res"},{"issue":"5","key":"2025092606220913600_bvaf133-B19","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1210\/clinem\/dgab928","article-title":"Effective GH replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3","volume":"107","author":"S\u00e4vendahl","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025092606220913600_bvaf133-B20","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1210\/clinem\/dgac517","article-title":"Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort","volume":"107","author":"Maghnie","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"2025092606220913600_bvaf133-B21","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.3390\/jcm10214988","article-title":"Isolated growth hormone deficiency and idiopathic short stature: comparative efficiency after growth hormone treatment up to adult height","volume":"10","author":"Ariza-Jimenez","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"2025092606220913600_bvaf133-B22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s43054-023-00173-y","article-title":"Growth hormone therapy response in children with short stature","volume":"71","author":"Gad","year":"2023","journal-title":"Egyptian Pediatric Association Gazette"},{"issue":"25","key":"2025092606220913600_bvaf133-B23","doi-asserted-by":"crossref","first-page":"e38350","DOI":"10.1097\/MD.0000000000038350","article-title":"Therapeutic efficacy of recombinant human growth hormone in children with different etiologies of dwarfism from a pharmacoeconomic point of view","volume":"103","author":"Ma","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2025092606220913600_bvaf133-B24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1515\/jpem-2020-0360","article-title":"PATRO children, a multi-center, non-interventional study of the safety and effectiveness of omnitrope(\u00ae) (somatropin) treatment in children: update on the United States cohort","volume":"34","author":"Backeljauw","year":"2021","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2025092606220913600_bvaf133-B25","author":"Electronic Medicines Compendium","year":"2022"},{"key":"2025092606220913600_bvaf133-B26","author":"Food and Drug Administration","year":"2017"},{"key":"2025092606220913600_bvaf133-B27","author":"Pharmaceuticals and Medical Devices Agency","year":"2022"},{"key":"2025092606220913600_bvaf133-B28","doi-asserted-by":"crossref","first-page":"925102","DOI":"10.3389\/fendo.2022.925102","article-title":"Height outcomes in Korean children with idiopathic short stature receiving growth hormone treatment","volume":"13","author":"Chae","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025092606220913600_bvaf133-B29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/CLEP.S42602","article-title":"The NordiNet\u00ae international outcome study and NovoNet\u00ae ANSWER program\u00ae: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (norditropin\u00ae)","volume":"5","author":"H\u00f6ybye","year":"2013","journal-title":"Clin Epidemiol"},{"issue":"10","key":"2025092606220913600_bvaf133-B30","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1210\/jc.2019-00775","article-title":"Treatment of children with GH in the United States and Europe: long-term follow-up from NordiNet\u00ae IOS and ANSWER program","volume":"104","author":"S\u00e4vendahl","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025092606220913600_bvaf133-B31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","article-title":"Using effect size-or why the P value is not enough","volume":"4","author":"Sullivan","year":"2012","journal-title":"J Grad Med Educ"},{"issue":"4","key":"2025092606220913600_bvaf133-B32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.20982\/tqmp.14.4.p242","article-title":"A review of effect sizes and their confidence intervals, part I: the Cohen's d family","volume":"14","author":"Goulet-Pelletier","year":"2018","journal-title":"Quant Method Psychol"},{"issue":"1","key":"2025092606220913600_bvaf133-B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000502231","article-title":"Diagnosis, genetics, and therapy of short stature in children: a growth hormone research society international perspective","volume":"92","author":"Collett-Solberg","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"11","key":"2025092606220913600_bvaf133-B34","first-page":"3990","article-title":"Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society","volume":"85","author":"Growth Hormone Research Society","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025092606220913600_bvaf133-B35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.arcped.2023.08.005","article-title":"Evaluation of the growth response of children with growth hormone deficiency according to the peak growth hormone levels in provocation tests","volume":"30","author":"Donbalo\u011flu","year":"2023","journal-title":"Archives de P\u00e9diatrie"},{"key":"2025092606220913600_bvaf133-B36","doi-asserted-by":"crossref","unstructured":"Phillip M, Abuzzahab M J, Pietropoli A, et al \u00a0Supplementary material for \u201cComparative Outcomes of GH Treatment in Pediatric Idiopathic Short Stature and GH Deficiency\u201d. 2025. Available from: 10.6084\/m9.figshare.30042241. Date of deposit 03 September 2025.","DOI":"10.1210\/jendso\/bvaf133"},{"issue":"10","key":"2025092606220913600_bvaf133-B37","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2174\/1389200216666151015112841","article-title":"Comparative study of growth hormone treatment in children with idiopathic short stature and growth hormone deficiency","volume":"16","author":"Jeong","year":"2015","journal-title":"Curr Drug Metab"},{"key":"2025092606220913600_bvaf133-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000542579","article-title":"Clinical predictors of good\/poor response to growth hormone treatment in children with idiopathic short stature","author":"Dauber","year":"2024","journal-title":"Horm Res Paediatr"},{"issue":"Suppl 2","key":"2025092606220913600_bvaf133-B39","first-page":"1","article-title":"Predictive factors of adult height after 2 years of GH replacement therapy in children with growth hormone deficiency (GHD)","volume":"95","author":"Mastromauro","year":"2022","journal-title":"Horm Res Paediatr"},{"key":"2025092606220913600_bvaf133-B40","doi-asserted-by":"crossref","first-page":"101331","DOI":"10.1016\/j.ghir.2020.101331","article-title":"Comparison of the efficacy and safety of recombinant human growth hormone in treating idiopathic short stature and growth hormone deficiency in children","volume":"53\u201354","author":"Hou","year":"2020","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"2025092606220913600_bvaf133-B41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.6065\/apem.2142110.055","article-title":"Response to growth hormone according to provocation test results in idiopathic short stature and idiopathic growth hormone deficiency","volume":"27","author":"Yoon","year":"2022","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"4","key":"2025092606220913600_bvaf133-B42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000500087","article-title":"Height gain and safety outcomes in growth hormone-treated children with idiopathic short stature: experience from a prospective observational study","volume":"91","author":"Child","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"4","key":"2025092606220913600_bvaf133-B43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4274\/jcrpe.2111","article-title":"The effect of recombinant growth hormone treatment in children with idiopathic short stature and low insulin-like growth factor-1 levels","volume":"7","author":"\u015e\u0131klar","year":"2015","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"10","key":"2025092606220913600_bvaf133-B44","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1515\/jpem-2021-0389","article-title":"Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment","volume":"34","author":"Soliman","year":"2021","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2025092606220913600_bvaf133-B45","doi-asserted-by":"crossref","first-page":"781044","DOI":"10.3389\/fendo.2021.781044","article-title":"GH resistance is a component of idiopathic short stature: implications for rhGH therapy","volume":"12","author":"Savage","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2025092606220913600_bvaf133-B46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jpeds.2004.08.055","article-title":"Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect","volume":"146","author":"Wit","year":"2005","journal-title":"J Pediatr"},{"issue":"2","key":"2025092606220913600_bvaf133-B47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2010.02.028","article-title":"Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database)","volume":"157","author":"Wilton","year":"2010","journal-title":"J Pediatr"},{"issue":"3","key":"2025092606220913600_bvaf133-B48","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000503783","article-title":"GHD diagnostics in Europe and the US: an audit of national guidelines and practice","volume":"92","author":"Binder","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"7","key":"2025092606220913600_bvaf133-B49","doi-asserted-by":"crossref","first-page":"e220504","DOI":"10.1530\/EC-22-0504","article-title":"Diagnosis and testing for growth hormone deficiency across the ages: a global view of the accuracy, caveats, and cut-offs for diagnosis","volume":"12","author":"Yuen","year":"2023","journal-title":"Endocr Connect"},{"issue":"11-12","key":"2025092606220913600_bvaf133-B50","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1159\/000521628","article-title":"Diagnosis of growth hormone deficiency remains a judgment call\u2014and that is good","volume":"94","author":"Allen","year":"2021","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2025092606220913600_bvaf133-B51","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s13063-023-07562-z","article-title":"The Growth Hormone Deficiency (GHD) reversal trial: effect on final height of discontinuation versus continuation of growth hormone treatment in pubertal children with isolated GHD\u2014a non-inferiority Randomised Controlled Trial (RCT)","volume":"24","author":"Brettell","year":"2023","journal-title":"Trials"},{"issue":"7","key":"2025092606220913600_bvaf133-B52","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eprac.2023.04.004","article-title":"Views on short stature of female vs male endocrine pediatric patients undergoing provocative growth hormone testing and their parents","volume":"29","author":"Kamoun","year":"2023","journal-title":"Endocr Pract"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvaf133\/64067944\/bvaf133.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/10\/bvaf133\/64067944\/bvaf133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/10\/bvaf133\/64067944\/bvaf133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:22:19Z","timestamp":1758882139000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf133\/8236488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,5]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf133","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,16]]},"article-number":"bvaf133"}}